Allergic Rhino-Conjunctivitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Allergic Rhino-Conjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions.
Allergic Rhino-Conjunctivitis is an allergen-induced inflammatory response mediated by IgE and most observed in children and most rare in children above 5 years and in adults. Allergens release by plants, herbs, pollens, animal dander, dust mites are common mediators. It is preferable to allergic rhinitis. The most common nasal symptoms are sneezing, irritability, itching, runny nose and non-nasal are redness, eye itching. Past or family history of allergens, physical symptoms like redness, nasal congestion, and laboratory findings skin prick test or IgE antibodies levels in blood are the diagnostics measures. Symptomatic care, treatment with antibiotics to prevent secondary infections, intranasal corticosteroids, antihistamines like cetirizine, levocetirizine for treating rhino conjunctivitis or runny nose. Antipyretic medications paracetamol, leukotriene receptor antagonist montelukast. The condition can be prevented by less exposure to known allergens, avoidance of cold foods.
The Allergic Rhino-Conjunctivitis drugs in development market research report provide comprehensive information on the therapeutics under development for Allergic Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhino-Conjunctivitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Allergic Rhino-Conjunctivitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Allergic Rhino-Conjunctivitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Allergic Rhino-Conjunctivitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Allergic Rhino-Conjunctivitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allergy Therapeutics PlcFaes Farma SA
HAL Allergy BV
Iltoo Pharma
Inmunotek SL
Marinomed Biotech AG
Roxall Medizin GmbH
Stallergenes Greer Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Allergic Rhino-Conjunctivitis reports